Retrospective Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 431-438
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.431
Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy
Hang-Yu Zhang, Jian-Hai Guo, Song Gao, Hui Chen, Xiao-Dong Wang, Peng-Jun Zhang, Peng Liu, Guang Cao, Hai-Feng Xu, Lin-Zhong Zhu, Ren-Jie Yang, Jian Li, Xu Zhu
Hang-Yu Zhang, Cancer Biotherapy Centre, the First Affiliated Hospital of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Jian-Hai Guo, Song Gao, Hui Chen, Xiao-Dong Wang, Peng-Jun Zhang, Peng Liu, Guang Cao, Hai-Feng Xu, Lin-Zhong Zhu, Ren-Jie Yang, Jian Li, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Li J and Zhu X designed the research; Zhang HY, Guo JH, Gao S, Zhang PJ and Chen H analyzed the data; Zhang HY wrote the paper; Wang XD, Yang RJ and Zhu X critically revised the manuscript for important intellectual content; Li J and Zhu X contributed equally to this work and should be considered co-first authors.
Supported by Capital Foundation of Medical Development (China), No. 2014-2-2154.
Institutional review board statement: This study has a statement on ethics approval by the Medical Ethics Committee of Beijing Tumor Hospital, which is a part of Beijing Cancer Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that was obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: The datasets generated during the current study are not publicly available due to usage in another ongoing study, but are available from the corresponding author upon reasonable request.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Xu Zhu, MD, Assistant Professor, Associate Professor, Doctor, Staff Physician, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com
Telephone: + 86-10-88196330 Fax: +86-10-88196330
Received: August 7, 2018
Peer-review started: August 8, 2018
First decision: September 12, 2018
Revised: September 19, 2018
Accepted: October 12, 2018
Article in press: October 12, 2018
Published online: November 15, 2018
Processing time: 100 Days and 10.5 Hours
ARTICLE HIGHLIGHTS
Research background

Previous studies have shown that left-sided colorectal cancer has a better survival prognosis than right-sided colorectal cancer. However, whether this prognosis difference is also present in liver metastasis colorectal cancer (CRC) patients treated with hepatic arterial infusion chemotherapy (HAIC) is still unknown.

Research motivation

Our study attempted to analyze for the first time, whether there would be a difference in survival and overall response rate in liver metastasis CRC patients treated with HAIC.

Research objectives

To analyze the overall survival and overall response rate difference of patients with liver metastasis of left-sided or right-sided colorectal cancer after HAIC.

Research methods

A retrospective analysis of liver metastasis CRC patients from May 2006 to August 2015 was conducted. Cox proportional hazard regression analysis was used to assess long-term survival outcomes.

Research results

Overall response rate was 28.9% in left-sided primary (LSP) patients, and 27.3% in right-sided primary (RSP) patients. Disease control rate was 76.3% in LSP patients and 69.7% in RSP patients. Median overall survival after HAIC was 16.3 mo in the LSP arm and 9.3 mo in the RSP arm (P = 0.164). Median progression-free survival was 5.7 mo in the LSP arm and 4.2 mo in the RSP arm (P = 0.851).

Research conclusions

The treatment response rate of HAIC in metastatic CRC patients is similar when compared by different primary tumor site. LSP patients seemed to have a superior survival compared to RSP patients when treated by HAIC but no significant difference was found.

Research perspectives

Further large sample size and multi-center prospective studies are needed to confirm the conclusion of this study.